Publications

Cancer cell

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

07-04-2009

PloS one

A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway.

12-03-2009

Biochimica et biophysica acta

Protein phosphatase 2A regulatory subunits and cancer.

01-01-2009

The international journal of biochemistry & cell biology

Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.

01-01-2009

Cell

RNAi Delivers Insights into Liver Cancer.

28-11-2008

The Journal of biological chemistry

Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity.

05-09-2008

Molecular cancer research : MCR

Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling.

01-09-2008

British journal of cancer

PRAME expression and clinical outcome of breast cancer.

05-08-2008

PLoS genetics

A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC.

01-12-2007

Proceedings of the National Academy of Sciences of the United States of America

A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.

06-11-2007

Cancer cell

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

01-10-2007

Nederlands tijdschrift voor geneeskunde

[The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference].

30-12-2006

The New England journal of medicine

Exploring the uses of RNAi--gene knockdown and the Nobel Prize.

07-12-2006

Cell

Re-evaluating cell-cycle regulation by E2Fs.

01-12-2006

Cell cycle (Georgetown, Tex.)

Senescence, wound healing and cancer: the PAI-1 connection.

01-12-2006

Cancer research

A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.

15-11-2006

Nature methods

shRNA libraries and their use in cancer genetics.

01-09-2006

The Journal of biological chemistry

A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta.

04-08-2006

Nature cell biology

Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence.

01-08-2006

The British journal of dermatology

An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis.

01-07-2006

Proceedings of the National Academy of Sciences of the United States of America

PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle.

04-04-2006

Nature chemical biology

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.

01-04-2006

Cell

A genomic and functional inventory of deubiquitinating enzymes.

02-12-2005

Methods in enzymology

Functional annotation of deubiquitinating enzymes using RNA interference.

09-11-2005

Nature cell biology

The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene.

01-11-2005

Cell

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

23-09-2005

Cold Spring Harbor symposia on quantitative biology

Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells.

25-08-2005

Cell

A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity.

17-06-2005

Cancer cell

A functional approach to questions about life, death, and phosphorylation.

01-06-2005

Molecular cell

The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway.

04-02-2005

Genes & development

PR72, a novel regulator of Wnt signaling required for Naked cuticle function.

01-02-2005

Blood

Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

01-01-2005

Oncogene

An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression.

24-06-2004

Nature

A large-scale RNAi screen in human cells identifies new components of the p53 pathway.

25-03-2004

The Journal of biological chemistry

High incidence of thymic epithelial tumors in E2F2 transgenic mice.

12-03-2004

Nature reviews. Cancer

New tools for functional mammalian cancer genetics.

01-10-2003

Nature

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.

14-08-2003

Molecular and cellular biology

Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation.

01-05-2003

The Journal of biological chemistry

Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53.

04-04-2003

The New England journal of medicine

A gene-expression signature as a predictor of survival in breast cancer.

19-12-2002

Cancer cell

Stable suppression of tumorigenicity by virus-mediated RNA interference.

01-09-2002

Nature

A progression puzzle.

22-08-2002

Cancer cell

E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest.

01-07-2002

Science (New York, N.Y.)

A system for stable expression of short interfering RNAs in mammalian cells.

19-04-2002

Cancer letters

Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle.

28-03-2002

Genes & development

A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.

15-03-2002

The Journal of biological chemistry

TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence.

22-02-2002

Nature cell biology

A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence.

01-02-2002

Nature

Gene expression profiling predicts clinical outcome of breast cancer.

31-01-2002

Cancer letters

B-myb rescues ras-induced premature senescence, which requires its transactivation domain.

28-09-2001

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway.

Protein phosphatase 2A regulatory subunits and cancer.

Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.

RNAi Delivers Insights into Liver Cancer.

Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity.

Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling.

PRAME expression and clinical outcome of breast cancer.

A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC.

A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

[The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference].

Exploring the uses of RNAi--gene knockdown and the Nobel Prize.

Re-evaluating cell-cycle regulation by E2Fs.

Senescence, wound healing and cancer: the PAI-1 connection.

A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.

shRNA libraries and their use in cancer genetics.

A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta.

Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence.

An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis.

PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle.

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.

A genomic and functional inventory of deubiquitinating enzymes.

Functional annotation of deubiquitinating enzymes using RNA interference.

The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene.

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells.

A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity.

A functional approach to questions about life, death, and phosphorylation.

The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway.

PR72, a novel regulator of Wnt signaling required for Naked cuticle function.

Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.

An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression.

A large-scale RNAi screen in human cells identifies new components of the p53 pathway.

High incidence of thymic epithelial tumors in E2F2 transgenic mice.

New tools for functional mammalian cancer genetics.

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.

Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation.

Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53.

A gene-expression signature as a predictor of survival in breast cancer.

Stable suppression of tumorigenicity by virus-mediated RNA interference.

A progression puzzle.

E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest.

A system for stable expression of short interfering RNAs in mammalian cells.

Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle.

A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.

TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence.

A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence.

Gene expression profiling predicts clinical outcome of breast cancer.

B-myb rescues ras-induced premature senescence, which requires its transactivation domain.

This site uses cookies